Has Saima Chohan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,933,419 in general payments to Saima Chohan, MD across 1,558 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Saima Chohan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Saima Chohan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Saima Chohan, MD

Rheumatology · Phoenix, AZNPI 1073675526

Payments from drug & device makers

$1,933,419in general payments, 2019–2025

Across 1,558 payments — averaging $1240.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$985K
Sun Pharmaceutical Industries Inc.$264K
Astrazeneca UK Limited$206K
Janssen Research & Development, LLC$81K
Dr.reddy's Laboratories,inc.$78K
Eli Lilly$58K
plus $261K from 49 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	290	$985,393
Sun Pharmaceutical Industries Inc.	217	$264,269
Astrazeneca UK Limited	6	$205,816
Janssen Research & Development, LLC	23	$80,779
Dr.reddy's Laboratories,inc.	44	$78,020
Eli Lilly	6	$57,818
E.r. Squibb & Sons, L.L.C.	42	$50,253
Gilead	15	$31,597
Tanabe Pharma America, Inc.	33	$30,442
Mitsubishi Tanabe Pharma Development America, Inc.	3	$25,880
Argenx US, Inc.	3	$24,306
Takeda Pharmaceuticals U.S.A., Inc.	6	$20,802
GSK	42	$18,031
Roche Products Limited	8	$13,080
Astrazeneca AB	1	$8,500
Sanofi US Services Inc.	15	$8,231
EMD Serono, Inc.	3	$8,140
Aurinia Pharma U.S., Inc.	3	$6,897
AbbVie	224	$4,559
UCB, Inc.	78	$2,135
Pfizer	115	$1,800
Johnson & Johnson(2 entities)	70	$1,260
Lilly USA, LLC	78	$883
Novartis	37	$705
Genentech USA, Inc.	32	$472
AstraZeneca(2 entities)	27	$431
Fresenius Kabi USA, LLC	15	$389
Sanofi	18	$386
Radius Health, Inc.	19	$367
Boehringer Ingelheim	14	$287
Mallinckrodt Hospital Products Inc.	10	$223
Sobi, Inc	7	$151
Actelion Pharmaceuticals US, Inc.	6	$136
Kyowa Kirin, Inc.	4	$109
Ferring Pharmaceuticals Inc.	6	$106
Octapharma USA, Inc.	2	$82
Pacira Therapeutics, Inc.	5	$78
ANI Pharmaceuticals, Inc.	3	$75
Intuitive Surgical	1	$69
Hikma Pharmaceuticals USA	5	$69
Bristol Myers Squibb	4	$56
Organon	2	$50
Merck	3	$42
Teva Pharmaceuticals USA, Inc.	2	$31
Pharming Healthcare, Inc.	1	$31
Mallinckrodt Enterprises LLC	1	$27
Zimmer Biomet	1	$27
Assertio Therapeutics, Inc.	1	$21
Boston Scientific	1	$21
Kiniksa Pharmaceuticals, Ltd.	1	$20
Sandoz	1	$20
Sanofi-aventis U.S. LLC	1	$15
Kiniksa Pharmaceuticals International, PLC	1	$14
Celltrion USA Inc.	1	$14
The Binding Site Inc.	1	$10

How this compares

$1,933,419 in reported general payments places this provider in the 85th percentile of 102 rheumatology providers in Arizona.

See all rheumatology providers in Arizona →

Medicare billing

Part B allowed, 2024

$6,581,921

Medicare patients

903

Services billed

322,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Phoenix

Nehad SolomanPhoenix$4.8M
John TesserPhoenix$4.8M
Swati BharadwajPhoenix$3.4M
Nikila KumarPhoenix$3.1M
Matthew HerrmannPhoenix$408K
Paul CaldronPhoenix$236K
Ramina Jajoo-FrindrichPhoenix$87K
Trent SmithPhoenix$9K
Alan MallacePhoenix$4K
Mona AminGlendale$5.5M

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →